Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aldosterone: a risk factor for vascular disease.

Mario Fritsch Neves1, Ernesto L Schiffrin

  • 1Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec, Canada H2W 1R7. schiffe@ircm.qc.ca

Current Hypertension Reports
|January 18, 2003
PubMed
Summary

Aldosterone receptor antagonism offers benefits for hypertensive patients, potentially mitigating cardiovascular events. This approach addresses the aldosterone escape phenomenon, protecting vasculature from harmful effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelin-1 overexpression in mice increases vascular Vegfa164 and Vegfa188 alternative splice isoforms via enhanced Khdrbs3 expression.

Journal of hypertension·2026
Same author

Response to letters about Hypertension Canada guideline.

Canadian family physician Medecin de famille canadien·2026
Same author

The Role of Renal Denervation in the Treatment of Hypertension in Canada: A Case-Based Discussion from the Canadian Hypertension Specialists Society.

American journal of hypertension·2025
Same author

Goodbye, Out With the Old and in With the New.

American journal of hypertension·2025
Same author

Overview of the 2025 American Heart Association/American College of Cardiology Blood Pressure Guideline: Perspective From Editors at the American Journal of Hypertension.

American journal of hypertension·2025
Same author

Aprocitentan: a new horizon in the treatment of hypertension.

Expert opinion on pharmacotherapy·2025

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Renin-angiotensin-aldosterone system blockade with ACE inhibitors or ARBs benefits hypertension but doesn't fully control cardiovascular events.
  • The aldosterone escape phenomenon may contribute to suboptimal outcomes in treated hypertensive patients.
  • Aldosterone directly impacts vasculature, causing hypertrophy, dysfunction, fibrosis, and injury.

Purpose of the Study:

  • To explore the role of aldosterone in cardiovascular events despite renin-angiotensin-aldosterone system blockade.
  • To highlight the therapeutic potential of aldosterone receptor antagonism in managing hypertension and its vascular complications.

Main Methods:

  • Review of animal models and clinical trials investigating aldosterone's effects.

Related Experiment Videos

  • Analysis of the aldosterone escape phenomenon in patients treated with ACE inhibitors or ARBs.

    • Main Results:

    • Aldosterone antagonism has demonstrated benefits in preclinical and clinical studies.
    • Hyperaldosteronism is more prevalent in "essential" hypertension than previously recognized.

    Conclusions:

    • Aldosterone receptor antagonism is a promising therapeutic strategy for hypertensive patients.
    • Blocking aldosterone action may protect the vasculature from detrimental effects, improving cardiovascular outcomes.
    • Increased recognition of hyperaldosteronism supports wider use of aldosterone blockers.